Related Experiment Video

Updated: Nov 7, 2025

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

12.1K

Cell-Based Therapies for Heart Failure

Antonio Carlos Campos de Carvalho1,2,3, Tais H Kasai-Brunswick2,3, Adriana Bastos Carvalho1,3

  • 1Laboratory of Cellular and Molecular Cardiology, Institute of Biophysics Carlos Chagas Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.

Frontiers in Pharmacology
|April 29, 2021
PubMed

Insights

Cell therapies offer a promising alternative for heart failure treatment when traditional methods fall short. Clinical trials are exploring various cell types and delivery methods to improve patient outcomes.

Area of Science:

  • Cardiovascular Medicine
  • Regenerative Medicine
  • Cell Therapy

Background:

  • Heart failure is a growing global epidemic, driven by aging populations and advances in cardiovascular care.
  • Current pharmacological treatments for heart failure, while effective, often yield suboptimal prognoses.
  • Heart transplantation, a last resort, faces limitations due to organ scarcity and immunosuppression complications.

Purpose of the Study:

  • To review the current landscape of cell therapies for heart failure.
  • To analyze the outcomes of clinical trials investigating cell-based treatments.
  • To discuss the future potential of cell therapies in managing heart failure.

Main Methods:

  • Systematic review of clinical trials on cell therapies for heart failure.
  • Analysis of data from various cell types and administration routes.
  • Evaluation of treatment efficacy and safety profiles.

Main Results:

  • Multiple clinical trials have explored diverse cell types and delivery methods for heart failure.
  • Results indicate potential benefits, but efficacy and optimal strategies require further investigation.
  • Challenges include cell engraftment, survival, and functional integration.

Conclusions:

  • Cell therapies represent a promising frontier in heart failure management, offering an alternative to transplantation.
  • Further research is needed to optimize cell types, delivery, and long-term outcomes.
  • Cell-based approaches hold potential for improving heart function and patient prognosis.

Keywords:
adult stem cellsbone marrow cellscell therapiesheart failurepluripotent cells (Min5–Max 8)

More Related Videos

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy11:51

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy

Published on: March 1, 2016

10.5K
Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

7.1K

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
71
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.3K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
118
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
68
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.1K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
907